Clinical Study On The Treatment Of HBeAg Positive Chronic Hepatitis B (Liver Stagnation And Spleen Deficiency Type) With Sini Powder And Danggui Shaoyao Powder

Objective : To evaluate the clinical study of Sini Powder combined with Danggui Shaoyao Powder in the treatment of HBeAg positive CHB based on syndrome differentiation.Methods : Sixty-four patients with HBeAg-positive CHB who met the inclusion criteria were selected and divided into treatment group and control group according to the random number table method,with 32 cases in each group.Four patients withdrew due to midway,and the final treatment group and control group were included in 30 cases.The control group was treated with tenofovir fumarate tablets(TAF)antiviral therapy,and the treatment group was combined with Sini Powder and Danggui Shaoyao Powder on the basis of the control group.The course of treatment was 24 weeks.The liver function(TBi L,ALT,AST),HBs Ag,HBeAg,HBV DNA were examined at the 0th,12 th and 24 th weeks of treatment.The liver hardness value(LSM),liver fiber four items(HA,PCIII,IV-C,LN),chitinase 3-like protein 1(CHI3L1)index and TCM symptom score were examined at 0 and 24 weeks.The efficacy of Sini Powder and Danggui Shaoyao Powder was analyzed and evaluated by statistical methods.Results : 1.Analysis of TCM symptom score : After 24 weeks of treatment,the total score of TCM symptoms in both groups,whether between groups or within groups,was lower than that before treatment,and the total score of the treatment group after treatment was lower than that of the control group.The difference was statistically significant(P<0.05).2.Efficacy analysis of TCM symptoms : After 24 weeks of treatment,the total effective rate of the treatment group was 86.67 %,and the total effective rate of the control group was 66.67 %.The difference was statistically significant(P<0.05).3.Efficacy analysis of liver function(TBi L,ALT,AST): The TBi L,ALT,AST indicators of the two groups of patients were improved to varying degrees at12 weeks and 24 weeks after treatment compared with those before treatment.The improvement of the indicators in the treatment group was significantly better than that in the control group,and the difference was statistically significant(P<0.05).4.HBs Ag efficacy analysis and negative conversion rate : After 12 weeks of treatment,the HBs Ag level of the treatment group after treatment was significantly lower than that before treatment,and the difference was statistically significant(P<0.05),while the HBs Ag level of the control group was compared with that before treatment.There was no statistically significant difference(P(29)0.05);after 24 weeks of treatment,the comparison between the two groups was significantly lower than that before treatment,with statistical significance(P<0.05),and the comparison between the two groups was tested by t test.The effect of the treatment group was better than that of the control group,and the difference was statistically significant(P<0.05).Throughout the study,the two groups of patients with HBs Ag negative rate was 0.5.HBeAg efficacy analysis and negative conversion rate : The HBeAg values of the two groups decreased at 12 weeks and 24 weeks after treatment compared with those before treatment.The differences between the two groups and within the group were statistically significant(P<0.05),and the HBeAg negative conversion rate of the treatment group was 3.3 %,while the HBeAg negative conversion rate of the control group was 0.6.HBV DNA efficacy analysis : 12 weeks and 24 weeks after treatment,HBV DNA in both groups decreased,and the difference was statistically significant compared with that before treatment and between the two groups(P<0.05).7.Analysis of the efficacy of liver fibrosis : The serum liver fibrosis four items(HA,PCIII,IV-C,LN),chitinase 3-like protein 1(CHI3L1),liver stiffness value(LSM)and other indicators of the two groups were significantly improved compared with those before treatment.The differences between the two groups and within the group were statistically significant(P<0.05).8.Safety analysis : There were no adverse reactions in the two groups during the treatment.There were no abnormalities in the detection of vital signs,blood routine,urine routine,stool routine,renal function and electrocardiogram.Conclusion : The classical prescription Sini Powder combined with Danggui Shaoyao Powder can improve the liver function index,reduce the level of HBs Ag and HBeAg,inhibit the replication of the virus,improve the liver fibrosis and relieve the clinical symptoms of the patients to a great extent,and provide a new direction for the treatment of chronic hepatitis B with traditional Chinese medicine combined with antiviral drugs.